DLI

BIOLOGICAL7 trials

Sponsors

University of Wisconsin, Madison, M.D. Anderson Cancer Center, Nantes University Hospital, Duke University, Nanfang Hospital, Southern Medical University

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Allogenetic Hematopoietic Stem Cell TransplantationB ALLLeukemiaLymphomaMRD-positiveMinimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

Phase 1

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

TerminatedNCT00582816

University of Wisconsin, MadisonLeukemia, Solid Tumors

Start: 2008-08-31End: 2015-08-31Updated: 2019-12-09

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

CompletedNCT01497184

M.D. Anderson Cancer CenterLeukemia, Lymphoma

Start: 2011-12-31End: 2021-03-08Updated: 2025-03-13

Adoptive Transfer of Haplo-identical DLI for AML and MDS

CompletedNCT02046122

Duke UniversityAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2014-07-31End: 2019-07-31Updated: 2020-12-03

Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Nantes University HospitalAcute Myeloid Leukemia (AML)

Start: 2021-11-10End: 2024-11-30Target: 12Updated: 2022-05-11

Phase 2

VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

CompletedNCT01541280

Nantes University HospitalAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2011-11-30End: 2015-07-31Updated: 2016-03-18

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityMinimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

Start: 2018-10-31End: 2022-10-31Target: 100Updated: 2018-09-07

Phase 3

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

RecruitingNCT07441291

Peking University People's HospitalAllogenetic Hematopoietic Stem Cell Transplantation, B ALL, MRD-positive

Start: 2025-11-30End: 2028-12-30Target: 70Updated: 2026-02-27

Related Papers

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma

Gene Therapy2021-04-13169 citations

Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2016-12-0212 citations

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

2016-08-02373 citations